Portugal – Antineoplastic and immunomodulating agents – 2023/0491 - BLINATUMOMAB [38.5 µG PÓ CONC SOL SOL INJ FRS]
Tender Description
BLINATUMOMAB [38.5 µG PÓ CONC SOL SOL INJ FRS]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
